tirzepatide · Eli Lilly
What should I know about Tirzepatide?
Tirzepatide by Eli Lilly: The molecule behind Mounjaro and Zepbound. Cost, side effects, dosing as labeled, comparisons and the latest news, all sourced.
Culture
Stopping & switching
Compounded & telehealth
Compounded Tirzepatide vs Zepbound: Cost and Differences in 2026Compounded tirzepatide used to cost a fraction of Zepbound. In 2026 the gap has largely closed. Here's an honest side-by-side on price, oversight, evidence, device and legal standing — and the hidden fees that make advertised numbers misleading.Compounded Tirzepatide: What It Is and Whether It's Legal in 2026Compounded tirzepatide is a pharmacy-mixed version of the active ingredient in Mounjaro and Zepbound. It is not FDA-approved. Since the shortage ended, only narrow patient-specific compounding remains lawful — here's what changed, what's still allowed, and what to ask.How to Spot Fake Mounjaro or ZepboundCounterfeit tirzepatide is sold on social media, through offshore websites and at some med-spas. Here is what a genuine Mounjaro or Zepbound pen looks like, what regulators and Eli Lilly have found inside fakes, and the checks you can run before you inject anything.Lilly vs the Compounders: The Legal Fight Over Tirzepatide, ExplainedEli Lilly has sued compounding pharmacies, telehealth platforms, medspas and peptide sellers over knockoff tirzepatide, and fought the compounders at FDA, in federal court and at the ITC. Here's who sued whom, what courts have decided, and what it means if you're a patient.
Cost & insurance
Does Medicare Cover Zepbound or Mounjaro?Medicare cannot cover a drug used only for weight loss, but there are now three separate doors to tirzepatide: Part D covers Mounjaro for type 2 diabetes, Part D can cover Zepbound for obstructive sleep apnea, and the Medicare GLP-1 Bridge covers the Zepbound KwikPen at $50 a month through 2027. Here is which door you qualify for.The Cheapest Way to Get Tirzepatide Legally in 2026Seven legal routes to tirzepatide, ranked by what they actually cost in 2026, with the catch attached to each. The cheapest legitimate route for most cash payers is Eli Lilly's own self-pay channel at $299 to $449 a month, and the biggest hidden cost is not the pharmacy you choose but the 45-day refill clock.
Side effects & safety
Does Zepbound Cause Hair Loss? What the Label and the Studies Actually SayHair loss is a listed Zepbound side effect with real numbers behind it. Here is how common it was in the trials, why it affected women far more than men, what the newest population studies found, and why researchers think rapid weight loss is doing most of the work.Mounjaro and Zepbound Lawsuits: What Is Actually Alleged, and Where the Cases StandA plain-English account of the tirzepatide litigation: which injuries are alleged, which courts are handling it, what Eli Lilly argues in its own filings, and what has and has not been decided as of September 2026.Mounjaro Side Effects: What the FDA Label Actually ReportsThe full list of Mounjaro (tirzepatide) side effects from the FDA prescribing information, with trial percentages, the ten warnings, what the four-year SURPASS-CVOT trial found, and how the Mounjaro label differs from Zepbound's.Tirzepatide vs Semaglutide Side Effects: What the Head-to-Head Evidence ShowsA direct comparison of Zepbound and Mounjaro against Wegovy and Ozempic on side effects, using the one randomized head-to-head trial, the best observational study, and the differences written into the two labels.Zepbound and Alcohol: What the Label Says, and Why People Report Drinking LessThere is no alcohol interaction on the Zepbound or Mounjaro label. The real concerns are indirect — dehydration, low blood sugar with insulin, and pancreatitis risk — and separately, a growing body of research finds people on tirzepatide drink less.Zepbound Side Effects: The Complete List and How Common Each One IsEvery Zepbound (tirzepatide) side effect that appears in the FDA prescribing information, with the actual trial percentage next to each one, plus the warnings, the contraindications and the things that are reported but not on the label.
Results & daily life
Exercise on GLP-1s: What the Evidence Actually ShowsStrength training and cardio while taking semaglutide or tirzepatide: what randomized trials, meta-analyses and society guidance say about muscle, results, and what happens after the drug stops — plus an honest map of what has never been tested.GLP-1 Plateau: Why Weight Loss Stalls and What the Research SaysPlateaus on semaglutide and tirzepatide are expected, measurable and well described in the trial data. Here is how researchers define a plateau, when it typically arrives, why it happens, and what the studies say about what comes next.How Fast Does Zepbound Work? What the Trial Curves ShowA month-by-month look at tirzepatide's weight-loss curve from SURMOUNT-1 and the FDA label — when the dose is reached, when most of the loss happens, when people plateau, and what happens to late responders.How Much Protein on a GLP-1? What Dietitians and the Research SayProtein targets on semaglutide and tirzepatide, where the numbers come from, why per-kilogram advice is confusing, what the body-composition data actually shows, and why protein alone will not do the job.
Specific groups
GLP-1 Drugs and Men's Health: Testosterone, Sex, Muscle and ResultsMen lose less percentage weight than women on the same dose, their testosterone tends to rise as they lose weight, the erectile function evidence points in two directions at once, and the muscle question is real. Here is what the 2025-2026 research actually found.GLP-1s After Bariatric Surgery: What the Evidence Says in 2026Weight coming back after gastric sleeve or bypass is common, and adding semaglutide or tirzepatide is now one of the most-studied responses to it. A 2026 randomized trial and a 208,000-patient US cohort finally give real numbers - here is what they found, and what nobody has tested yet.GLP-1s and Menopause: What the Research Actually ShowsMenopause changes where your body stores fat and how much energy you burn, and GLP-1 drugs work in perimenopausal and postmenopausal women about as well as they work in younger women. The newer and more interesting question is whether menopause hormone therapy makes them work even better - here is what the evidence says, and what it does not say.GLP-1s Over 65: What the Data Actually ShowsNo GLP-1 label sets an age limit or an age-based dose, and trial analyses in adults 65 and older find efficacy close to younger adults. The real differences are tolerability, muscle and function, one specific fracture observation in the Wegovy label, and the fact that Medicare will not pay for weight loss.
How they work
How Does Mounjaro Work? The Science Behind Tirzepatide, in Plain EnglishMounjaro is tirzepatide, a once-weekly injection for type 2 diabetes that copies two gut hormones instead of one. Here is what it does to insulin, glucagon, your stomach and your appetite, straight from the FDA label and the research behind it.How Does Zepbound Work? GIP and GLP-1 ExplainedZepbound is tirzepatide, the same molecule as Mounjaro, approved for weight management and sleep apnea. It activates two gut hormone receptors - GIP and GLP-1 - and this guide explains what each one does to appetite, fat tissue and the brain.How Long Does Tirzepatide Stay in Your System?Tirzepatide has a half-life of about five days, so after a last dose it takes roughly three and a half to four weeks to clear. Here is what the label says about half-life, steady state, missed doses, washout and what happens when you stop.Semaglutide vs Tirzepatide: How the Two Drugs Actually DifferSemaglutide hits one receptor, tirzepatide hits two - and in the only head-to-head trial, tirzepatide produced more weight loss, though the two molecules differ in more ways than a single number captures.Tirzepatide and Birth Control: What the Label Actually SaysMounjaro and Zepbound are the only once-weekly GLP-1-family drugs whose US labels carry a specific oral contraceptive warning. Here is the exact wording, the study numbers behind it, and how it differs from semaglutide.
Clinical trials
How Much Weight Do People Lose on Zepbound? The Numbers From Every TrialEvery published tirzepatide weight-loss figure in one place — by dose, by population, by trial, and by how it was measured — plus what the same drug does outside of a clinical trial.Semaglutide vs Tirzepatide Head to Head: What SURMOUNT-5 FoundSURMOUNT-5 is the only large randomized trial that pitted tirzepatide directly against semaglutide at obesity doses — here are the numbers, the caveats, and what the trial could not measure.SURPASS-CVOT Explained: What the Big Tirzepatide Heart Trial Actually ShowedThe 13,299-person trial that tested Mounjaro against Trulicity for heart attacks, strokes and deaths — what non-inferiority means, why the mortality number comes with a caveat, and what is still unanswered.What Happens When You Stop Taking Zepbound? What SURMOUNT-4 and SURMOUNT-MAINTAIN FoundThe two randomized trials that tested stopping tirzepatide — what people regained, how fast, and what happened to the group that lowered their dose instead of quitting.What the Clinical Trials Actually Show About TirzepatideA plain-English tour of the tirzepatide evidence base — the SURPASS diabetes trials, the SURMOUNT obesity trials, the heart and sleep apnea studies, what the numbers were, and where the evidence still runs out.
FDA & regulation
Is Compounded Tirzepatide Legal in 2026? What the FDA Actually SaysLarge-scale compounding of tirzepatide copies lost its legal basis on February 18, 2025 for pharmacies and March 19, 2025 for outsourcing facilities. A narrow path remains for small-volume, patient-specific compounding, and the FDA has spelled out where the line sits.Is Semaglutide Still in Shortage? What the FDA List Says in 2026The FDA declared the semaglutide injection shortage resolved on February 21, 2025, and it has not returned since, which is why compounded copies of Ozempic and Wegovy are no longer generally legal.Is Tirzepatide Still in Shortage? The Full Mounjaro and Zepbound TimelineTirzepatide came off the FDA drug shortage list on October 2, 2024, was put back under review after a lawsuit, and was declared resolved again on December 19, 2024. It has stayed off the list ever since, and courts have upheld that decision twice.The Complete FDA Approval History of Tirzepatide (Mounjaro and Zepbound)Tirzepatide has two US brand names, two application numbers and six separate approved uses. Here is every FDA decision from the May 13, 2022 Mounjaro approval through the August 2026 cardiovascular indication, with the supplement numbers and trial names behind each one.Tirzepatide Approvals Around the World: Mounjaro and Zepbound by CountryTirzepatide is approved in the US, EU, UK, Canada, Japan, China, Australia, India and beyond, but the brand names and the approved uses differ by country. In the UK and EU, Mounjaro is also the weight-loss brand, which trips up a lot of American readers.
Beyond weight loss
Microdosing Zepbound: What's Actually KnownNo randomized trial has ever tested intentional microdosing of tirzepatide. But 2026 brought three things that change the conversation: a US multi-dose pen, a randomized trial of dose reduction, and an FDA proposal to shut down compounded supply.Tirzepatide and Heart Failure: The SUMMIT Trial ExplainedSUMMIT was the first trial to show a drug could change the course of obesity-related heart failure with preserved ejection fraction. It cut heart failure events by 38 percent. It still did not produce an approved indication in the United States or Europe, and the reasons why are worth understanding.Tirzepatide for PCOS: What the Evidence Actually ShowsTirzepatide is not approved for polycystic ovary syndrome anywhere. One small randomized trial, a large real-world cohort and a newly launched phase 4 trial are the whole evidence base — and they point in a specific, limited direction.What Else Can Tirzepatide Treat? Beyond Weight Loss and DiabetesTirzepatide has exactly four FDA-approved uses in the United States, split across two brand names. Everything else you have read about it — heart failure, fatty liver, PCOS, addiction, dementia — sits somewhere on a long ladder between a strong trial and a hopeful database study.Zepbound for Sleep Apnea: What the Evidence Actually ShowsZepbound is the first and only medication the FDA has approved for obstructive sleep apnea. The trial behind it is strong, the effect is large, and the two questions nobody can answer yet are whether it replaces CPAP and what happens if you stop.
Medications
FAQ
Alternatives
Pipeline
Retatrutide: What to Know About the Triple AgonistRetatrutide produced the biggest weight-loss numbers ever reported in a Phase 3 obesity trial, but it is not approved, not available, and comes with side effects worth understanding before the hype.When Will Generic Ozempic Be Available in the US?Generic semaglutide is already on sale in India and Canada, but the US patent situation pushes an American generic to the end of 2031 at the earliest. Here is the timeline and what is available in the meantime.
How-to guides
Liraglutide
Market & policy
News
Companies
Recent Tirzepatide news
Full timeline- Safety
Still no NAION warning on any US tirzepatide label
- Research
Tirzepatide evidence base: what has reported and what has not
- Compounding
Branded tirzepatide self-pay prices sit far below the shortage-era gap
- Business
Citi raises its Lilly price target to $1,600 after a month of share weakness
- Science
Eloralintide moves into Phase 3 alone and in combination with tirzepatide
- Safety
Ukraine charges 27 in a falsified tirzepatide manufacturing ring
- Competition
Lilly's tirzepatide reaches about 57% of the US GLP-1 market
- Safety
Pharmacovigilance study flags Wernicke encephalopathy with semaglutide and tirzepatide